Medivir's MIV-210 (FLG) inhibits hepatitis B virus, according to published report

By Lisa Kerner

Erie, Pa., March 28 - Medivir said the March edition of Antimicrobial Agents and Chemotherapy features a report that the company's antiviral MIV-210 (FLG) in laboratory assays is active against lamivudine- and adefovir-resistant hepatitis B virus (HBV), a common form of jaundice.

Medivir said the study authors consider MIV-210 (FLG) suitable for treatment of drug-resistant HBV and as first-line therapy together with adefovir.

In previously published trials, chronically HBV-infected woodchucks have been treated with lamivudine, adefovir or MIV-210 (FLG), with MIV-210 (FLG) demonstrating superior antiviral efficacy, according to a company news release.

Sales of HBV pharmaceuticals are expected to reach $1 billion annually by 2010, the release stated.

Phase 2a clinical trials with MIV-210 (FLG) are also underway in HIV patients, Medivir said.

Medivir, based in Huddings, Sweden, develops pharmaceuticals for widely prevalent diseases with proteases as the target enzyme.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.